Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Livedo: benign livedo reticularis (no tests) or livedo racemosa (initial work-up)

Internal medicine and immunology · Symptom or situation · updated 2026-10-30

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: Livedo racemosa is the most common skin manifestation of antiphospholipid syndrome: it is present in 25% of patients with primary APS and in 70% of those whose APS is associated with lupus (literature review, non-French data) [1].

Benign livedo reticularis (fine, closed mesh, symmetrical, cold-related, isolated): no tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Livedo racemosa or suspicious livedo: first tests

Laboratory tests (fasting from fat if cryoglobulins)

12 weeks later, if an antiphospholipid antibody is positive

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Sources (9)
  1. Sajjan VV, Lunge S, Swamy MB, Pandit AM. Livedo reticularis: a review of the literature. Indian Dermatol Online J. 2015;6(5):315-21.
  2. Centre de référence du lupus, syndrome des anticorps antiphospholipides et autres maladies auto-immunes rares ; centre de référence RAISE ; filière FAI²R. Protocole national de diagnostic et de soins (PNDS) : syndrome des anti-phospholipides de l'adulte et de l'enfant. Haute Autorité de santé, octobre 2022.
  3. Ngan V, de Menezes S, Oakley A. Livedo reticularis. DermNet (Nouvelle-Zélande), 2003, mise à jour en septembre 2016.
  4. Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270 (également Arthritis Rheumatol. 2023;75(10):1687-1702).
  5. Arachchillage DRJ, Gomez K, Alikhan R, Anderson JAM, Lester W, Laffan M; British Society for Haematology. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012: use of direct acting oral anticoagulants. Br J Haematol. 2020;189(2):212-215.
  6. Centre de référence des maladies auto-immunes systémiques rares d'Île-de-France ; filière FAI²R (coordination : Cacoub P). Protocole national de diagnostic et de soins (PNDS) : cryoglobulinémies. Haute Autorité de santé, juin 2021.
  7. Arachchillage DJ, Platton S, Hickey K, et al.; BSH Committee. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2024;205(3):855-880.
  8. Tripodi A, Cohen H, Devreese KMJ. Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18(7):1569-1575.
  9. Lee PY, Davidson BA, Abraham RS, et al. Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement. JAMA Netw Open. 2023;6(5):e2315894.